NASDAQ: TEVA

Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), based in China, has entered into a cooperation agreement with Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), securing exclusive commercialization rights for Austedo (deutetrabenazine) in mainland China. Austedo, a vesicle monoamine transporter 2 (VMAT2) inhibitor, received its initial approval in the U.S. in 2017…